Cone Snail Venom Shows Potential for Treating Severe Malaria

Cone Snail, Venom, Malaria, COVID-19, Blockage Therapies, Anti-adhesion Drugs, Conotoxins, Emerging Diseases, Pathology

Conus nux, a species of sea snail (Photo credit: Fred Pflueger, Ph.D.)

By gisele galoustian | 2/18/2021

Severe forms of malaria such as Plasmodium falciparum may be deadly even after treatment with current parasite-killing drugs. This is due to persistent cyto-adhesion of infected erythrocytes even though existing parasites within the red blood cells are dead. As vaccines for malaria have proved less than moderately effective, and to treat these severe cases of P. falciparum malaria, new avenues are urgently needed. Latest estimates indicate that more than 500 million cases of malaria and more than 400,000 deaths are reported worldwide each year. Anti-adhesion drugs may hold the key to significantly improving survival rates.

Using venom from the Conus nux, a species of sea snail, a first-of-its-kind study from �鶹��ýӳ��’s in collaboration with FAU’s and the , , United States Department of Commerce, suggests that these conotoxins could potentially treat malaria. The study provides important leads toward the development of novel and cost-effective anti-adhesion or blockade-therapy pharmaceuticals aimed at counteracting the pathology of severe malaria.

Results, published in the , expand the pharmacological reach of conotoxins/ conopeptides by revealing their ability to disrupt protein-protein and protein-polysaccharide interactions that directly contribute to the disease. Similarly, mitigation of emerging diseases like AIDS and COVID-19 also could benefit from conotoxins as potential inhibitors of protein-protein interactions as treatment. Venom peptides from cone snails has the potential to treat countless diseases using blockage therapies.

“Molecular stability, small size, solubility, intravenous delivery, and no immunogenic response make conotoxins excellent blockade-therapy candidates,” said , Ph.D., corresponding author and a professor of biomedical science, FAU’s Schmidt College of Medicine. “Conotoxins have been vigorously studied for decades as molecular probes and drug leads targeting the central nervous systems. They also should be explored for novel applications aimed to thwart amiss cellular responses or foil host parasite interactions through their binding with endogenous and exogenous proteins. Further investigation is likely to yield breakthroughs in fields continuously toiling for more efficient therapeutic approaches such as cancer, autoimmune diseases, novel emerging viral diseases as well as malaria where venom-based peptidic natural products can be put into practice.”

The disruption of protein-protein interactions by conotoxins is an extension of their well known inhibitory action in many ion channels and receptors. Disabling prey by specifically modulating their central nervous system is a ruling principle in the mode of action of venoms.

“Among the more than 850 species of cone snails there are hundreds of thousands of diverse venom exopeptides that have been selected throughout several million years of evolution to capture their prey and deter predators,” said , Ph.D., corresponding author and senior advisor for biochemical sciences at the National Institute of Standards and Technology. “They do so by targeting several surface proteins present in target excitable cells. This immense biomolecular library of conopeptides can be explored for potential use as therapeutic leads against persistent and emerging diseases affecting non-excitable systems.”

For the study, researchers used high-throughput assays to study Conus nux collected off the Pacific coast of Costa Rica. They revealed the in vitro capacity of cone snail venom to disrupt protein-protein and protein-polysaccharide interactions that directly contribute to pathology of P. falciparum malaria. They determined that six fractions from the venom inhibit the adhesion of recombinant P. falciparum erythrocyte membrane protein 1 (PfEMP-1) domains to their corresponding receptors, which express on the endothelial microvasculature and the placenta.

The results are noteworthy as each of these six venom fractions, which contain a mostly single or a very limited set of peptides, affected binding of domains with different receptor specificity to their corresponding receptors, which are proteins (CD36 and ICAM-1), and polysaccharide. This activity profile suggests that the peptides in these conotoxin fractions either bind to common structural elements in the different PfEMP1 domains, or that a few different peptides in the fraction may interact efficiently (concentration of each is lower proportionally to the complexity) with different domains.

Study co-authors are Alberto Padilla, Ph.D., first author and a former graduate student, FAU’s Schmidt College of Medicine; Sanaz Dovell, Ph.D., a former student in FAU’s Charles E. Schmidt College of Science; Olga Chesnokov, Ph.D., research associate, FAU’s Schmidt College of Medicine; and Mickelene Hoggard, Ph.D., Chemical Sciences Division, National Institute of Standards and Technology.

This research is supported in part by the National Institute of Allergy and Infectious Diseases (grants R21A137721 and R01AI092120) awarded to Oleinikov.

-FAU-